Business Description
Ernexa Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1140823089
Share Class Description:
ERNA: Ordinary SharesTotal Employee Number:
5Description
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 23.59 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 73.6 | |||||
3-Year EPS without NRI Growth Rate | 78 | |||||
3-Year FCF Growth Rate | 78.1 | |||||
3-Year Book Growth Rate | -79.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 70.76 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 17.81 | |||||
9-Day RSI | 26.35 | |||||
14-Day RSI | 31.99 | |||||
3-1 Month Momentum % | 31.46 | |||||
6-1 Month Momentum % | -79 | |||||
12-1 Month Momentum % | -88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.89 | |||||
Quick Ratio | 2.89 | |||||
Cash Ratio | 2.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -182 | |||||
Shareholder Yield % | 125.83 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -502.78 | |||||
ROA % | -161.78 | |||||
ROIC % | -232.99 | |||||
3-Year ROIIC % | -242.85 | |||||
ROC (Joel Greenblatt) % | -2542.09 | |||||
ROCE % | -557.06 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.67 | |||||
Price-to-Tangible-Book | 0.67 | |||||
EV-to-EBIT | 0.28 | |||||
EV-to-EBITDA | 0.29 | |||||
EV-to-FCF | 0.58 | |||||
| Price-to-Net-Current-Asset-Value | 0.72 | |||||
| Price-to-Net-Cash | 0.83 | |||||
Earnings Yield (Greenblatt) % | 357.14 | |||||
FCF Yield % | -157.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ERNA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ernexa Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -26.2 | ||
| Beta | 3.0876 | ||
| 3-Year Sharpe Ratio | -0.29 | ||
| 3-Year Sortino Ratio | -0.53 | ||
| Volatility % | 237.12 | ||
| 14-Day RSI | 31.99 | ||
| 14-Day ATR ($) | 0.894152 | ||
| 20-Day SMA ($) | 5.90621 | ||
| 12-1 Month Momentum % | -88 | ||
| 52-Week Range ($) | 3.1829 - 71.4975 | ||
| Shares Outstanding (Mil) | 1.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ernexa Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ernexa Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 102 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 17 days | ||
| General meeting for 2026 | 2026-07-01 11:00 | 6.65 (-0.30%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 7.53 (-2.71%) | ||
| 0.04:1 Stock Split | 2026-05-04 | 3.81 (-0.33%) | ||
| Annual report for 2025 | 2026-03-13 | 7.73 (+5.42%) | ||
| Virtual Investor Closing Bell Series | 2026-02-25 16:00 | 7.66 (+2.17%) | ||
| Third quarter earnings results for 2025 | 2025-11-07 | 42.25 (-2.31%) | ||
| Annual Cell & Gene Meeting on the Mesa conference | 2025-10-07 14:45 | 34.00 (+8.80%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 42.25 (+0.60%) |
Show
Entries
Ernexa Therapeutics Inc Frequently Asked Questions
What is Ernexa Therapeutics Inc(ERNA)'s stock price today?
The current price of ERNA is $3.92. The 52 week high of ERNA is $71.50 and 52 week low is $3.18.
When is next earnings date of Ernexa Therapeutics Inc(ERNA)?
The next earnings date of Ernexa Therapeutics Inc(ERNA) is 2026-08-13 Est..
Does Ernexa Therapeutics Inc(ERNA) pay dividends? If so, how much?
Ernexa Therapeutics Inc(ERNA) does not pay dividend.
Guru Commentaries on NAS:ERNA
No articles.
Press Release
Articles on Ernexa Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers